{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:38:58Z","timestamp":1786984738330,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.arteri.2020.09.002","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T09:02:17Z","timestamp":1607850137000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-6468","authenticated-orcid":false,"given":"Walter","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Lavalle-Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Molinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2020.09.002_bib0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2020.09.002_bib0185","doi-asserted-by":"crossref","DOI":"10.1007\/s40256-020-00399-w","article-title":"A review of the efficacy and tolerability of bempedoic acid in the treatment of hypercholesterolemia","author":"Niman","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.arteri.2020.09.002_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","article-title":"Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis","volume":"30","author":"Burke","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.arteri.2020.09.002_bib0195","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0200","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0205","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arteri.2020.09.002_bib0210","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2020.09.002_bib0215","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2020.09.002_bib0220","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.arteri.2020.09.002_bib0225","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy","volume":"117","author":"Ballantyne","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2020.09.002_bib0230","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2020.09.002_bib0235","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40265-020-01308-w","article-title":"Bempedoic acid: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.arteri.2020.09.002_bib0240","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.2174\/1381612822666161230142931","article-title":"Inflammation: a novel therapeutic target\/direction in atherosclerosis","volume":"23","author":"Li","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.arteri.2020.09.002_bib0245","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5603\/KP.a2019.0013","article-title":"Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials","volume":"77","author":"Wang","year":"2019","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.arteri.2020.09.002_bib0250","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.arteri.2020.09.002_bib0255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.arteri.2020.09.002_bib0260","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jonm.12936","article-title":"A systematic review and meta-analysis on the structured handover interventions in improving patient safety outcomes","volume":"28","author":"Bukoh","year":"2020","journal-title":"J Nurs Manag"},{"key":"10.1016\/j.arteri.2020.09.002_bib0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12874-016-0184-5","article-title":"Two new methods to fit models for network meta-analysis with random inconsistency effects","volume":"16","author":"Law","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.arteri.2020.09.002_bib0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.arteri.2020.09.002_bib0275","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/AphA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2020.09.002_bib0280","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2020.09.002_bib0285","doi-asserted-by":"crossref","first-page":"pii:E22","DOI":"10.3390\/jcm9010022","article-title":"Statin-related myotoxicity: a comprehensive review of pharmacokinetic pharmacogenomic and muscle components","volume":"9","author":"Turner","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0290","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/phar.2074","article-title":"Evolving role of non-statin therapy for the management of dyslipidemia and cardiovascular risk reduction: past present, and future","volume":"38","author":"Sisson","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.arteri.2020.09.002_bib0295","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0300","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0305","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0310","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-019-1080-x","article-title":"Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol","volume":"18","author":"Su","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.arteri.2020.09.002_bib0315","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2796.2005.01556.x","article-title":"Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis","volume":"258","author":"Olofsson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0320","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.M035212","article-title":"ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK","volume":"54","author":"Filippov","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2020.09.002_bib0325","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2020.09.002_bib0330","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0335","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2020.09.002_bib0340","article-title":"A review of bempedoic acid: a new drug for an old problem","volume":"16","author":"Nguyen","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.arteri.2020.09.002_bib0345","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40264-020-00931-6","article-title":"Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies","volume":"43","author":"Cicero","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.arteri.2020.09.002_bib0350","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00467-018-3979-2","article-title":"Uric acid and progression of chronic kidney disease","volume":"34","author":"Weaver","year":"2019","journal-title":"Pediatr Nephrol"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916820300917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916820300917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:33:06Z","timestamp":1759325586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916820300917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0214916820300917"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2020.09.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2020.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}